NeuroPace, Inc. (NPCE)

NGM – Real Time Price. Currency in USD

14.68

-0.37 (-2.46%)

Market open: Aug 12, 2026, 2:32 PM EDT

14.33

-0.72 (-4.78%)

Previous after-hours: Aug 11, 2026, 7:35 PM EDT

12.08.2026

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.

12.08.2026

NeuroPace Q2 Earnings Call Highlights

NeuroPace NASDAQ: NPCE reported second-quarter revenue growth driven by continued adoption of its RNS System for adult focal epilepsy, while raising its full-year revenue and adjusted EBITDA outlook. The company also said it is pursuing additional discussions with the U.S. Food and Drug Administration regarding its application to expand the RNS System's indication into idiopathic generalized epilepsy, or IGE.

11.08.2026

NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates

NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.26 per share a year ago.

11.08.2026

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. Second Quarter 2026 Financial Highlights Total revenue of $22.8 million in the second quarter of 2026 RNS System revenue of $22.5 million in the quarter, representing 21.3% growth compared to the second quarter of 2025 Net los.

Videos

No Data

There is no data to display

Press releases

11.08.2026

NeuroPace, Inc. (NPCE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

NeuroPace, Inc. (NPCE)

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace Q2 Earnings Call Highlights

NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Videos

No Data

Press releases

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace Q2 Earnings Call Highlights

NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Videos

No Data

Press releases

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Search stocks

NeuroPace, Inc. (NPCE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

NeuroPace, Inc. (NPCE)

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace Q2 Earnings Call Highlights

NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Videos

No Data

Press releases

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace Q2 Earnings Call Highlights

NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Videos

No Data

Press releases

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance